Product information
From Health Canada
No match found
No other product was found with the same active ingredient group.
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Approved
Current status date:
2018-04-06
Product name:
ARBESDA RESPICLICK
DIN:
02474646
Product Monograph/Veterinary Labelling:
Date:
2018-12-21
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
TEVA CANADA LIMITED
30 Novopharm Court
Toronto
Ontario
Canada
M1B 2K9
Class:
Human
Dosage form(s):
Powder (Metered Dose)
Route(s) of administration:
Inhalation
Number of active ingredient(s):
2
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
12:12.08.12
Anatomical Therapeutic Chemical (ATC): See footnote 4
R03AK06 SALMETEROL AND FLUTICASONE
Active ingredient group (AIG) number:See footnote5
0238341009
| Active ingredient(s) | Strength |
|---|---|
| FLUTICASONE PROPIONATE | 232 MCG / ACT |
| SALMETEROL (SALMETEROL XINAFOATE) | 14 MCG / ACT |